Relative Contribution of Brain Insulin Action for Postprandial Metabolism

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to clarify (i) the contribution of brain insulin action on regulation of systemic metabolism, (ii) sex-specific differences in the central regulation and (iii) the influence of the menstrual cycle in women. Therefore, participants will undergo oral glucose tolerance tests combined with a double tracer dilution technique. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray.

Clinical Trial Description

This research project aims to investigate to what extent brain insulin action is responsible for the control of postprandial metabolism compared to direct effects of insulin in peripheral target tissues. Furthermore, the study will investigate sex differences and the influence of the menstrual cycle on brain-derived coordination of postprandial signaling for metabolic control. Therefore, insulin action in the brain will be introduced by application of insulin as nasal spray (on one day) versus carrier solution as placebo nasal spray (on another day) in a randomized, blinded fashion. Spray administration will be performed 15 minutes before a 75 gram oral glucose tolerance test that will introduce a postprandial state. On placebo day, the known spillover of tiny amounts of nasal insulin into the systemic circulation will be mimicked by an appropriate i.v. insulin bolus. This approach will be combined with a double-tracer dilution technique. Labeled glucose ([6,6-2H]glucose) will be infused 120 minutes before and during the OGTT (180 min) and will be used to address endogenous glucose production. The glucose drink from the OGTT will be enriched with [U-13C6]glucose to compute the glucose appearance rate (Ra). Basal endogenous glucose production will be calculated as well as post-load endogenous glucose production and rates of glucose disappearances (Rd). Using this approach, brain-derived regulation of postprandial metabolism including endogenous glucose production, glucose disappearance, insulin secretion, and secretion of proglucagon-cleavage products (incretins) will be examined. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06295640
Study type	Interventional
Source	University of Ulm
Contact	Martin Heni, MD
Phone	+4973150044505
Email	martin.heni@uniklinik-ulm.de
Status	Recruiting
Phase	N/A
Start date	March 18, 2024
Completion date	January 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081037` - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)	N/A
Recruiting	`NCT05544266` - Rare and Atypical Diabetes Network
Recruiting	`NCT04039763` - RT-CGM in Young Adults at Risk of DKA	N/A
Active, not recruiting	`NCT05505994` - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin	Phase 3
Completed	`NCT03623113` - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes	N/A
Completed	`NCT03623139` - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes	N/A
Completed	`NCT03359629` - Spectrophon LTD Glucometry Monitor Accuracy
Recruiting	`NCT03682640` - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes	Phase 2
Completed	`NCT02697305` - Incretin Effects of Branched Chain Amino Acids	N/A
Completed	`NCT01737164` - Effect of Age on Glucose and Lipid Metabolism	N/A
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Recruiting	`NCT03613688` - Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control	N/A
Completed	`NCT04098549` - The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes	N/A
Terminated	`NCT04031404` - Glucose and Non-Invasive Brain Stimulation	N/A
Active, not recruiting	`NCT03577964` - Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
Active, not recruiting	`NCT03232008` - Canderel:Effects on Blood Glucose Concentration and Appetite Scores	N/A
Completed	`NCT04042142` - Glucagon Resistance in Patients With NAFLD	N/A
Active, not recruiting	`NCT05607745` - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study	N/A
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT04082923` - Effect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relative Contribution of Brain Insulin Action for Postprandial Metabolism — BrainInsPPM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms